Reframing risks in rare diseases: economics of networks, spillovers, and scale

Carlisle Ford Runge, James Campbell, Carlisle P. Runge

Research output: Contribution to journalArticlepeer-review

Abstract

Rare diseases affect over three hundred million individuals globally. Investment in research and development remains incommensurate with the challenges rare diseases pose. Further investment in information sharing platforms to promote common and standardized network technologies for rare disease is needed. Rare disease R&D generates information and assets that spill over in other ways, providing benefits that may not be apparent to investors ex ante. Analytical and computational methods recently applied at scale are promising. One important way of achieving efficiencies of scale in R&D is clustering rare diseases into groups with similar traits.

Original languageEnglish (US)
Article number1516725
JournalFrontiers in Pharmacology
Volume15
DOIs
StatePublished - 2024

Bibliographical note

Publisher Copyright:
Copyright © 2024 Runge, Campbell and Runge.

Keywords

  • basket trials
  • clustering
  • drug repurposing
  • economics
  • networks
  • rare diseases
  • scale
  • spillovers

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Reframing risks in rare diseases: economics of networks, spillovers, and scale'. Together they form a unique fingerprint.

Cite this